Dr. Percy Po-Yih Lee, MD

Dr. Lee practices at City of Hope National Medical Cente - City of Hope Lennar Oncology/Infusion - HOPD in Irvine, California.

Dr. Lee's NPI, 1447442504, was assigned on August 13, 2007. Dr. Lee graduated from Harvard Medical School in 2003. Dr. Lee holds California license A88897.

Dr. Lee's primary practice is City of Hope National Medical Cente - City of Hope Lennar Oncology/Infusion - HOPD, at 1000 Fivepoint, Irvine, CA 92618.

Dr. Lee's primary practice is City of Hope National Medical Cente - City of Hope Lennar Oncology/Infusion - HOPD in Irvine, California. The medical group on file is City of Hope. Dmand AI also links Dr. Lee to 1 more group practice or clinic and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lee practices, 3 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Lee's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Lee is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Lee's licenses on file in 4 states: California, Florida, Texas and Oklahoma.

Dmand AI lists anal cancer radiation, bladder cancer radiation, bone cancer radiation, brain cancer radiation, cancer radiation-upper GI, colorectal cancer radiation, lung cancer radiation and lymphoma radiation among the conditions Dr. Lee treats.

CMS data shows 4,571 Medicare services from Dr. Lee across 14 procedure codes in 2024, for 312 Medicare patients. Medicare paid $450,199 for them. Every service was in an office.

CMS counts 312 Medicare patients who saw Dr. Lee in 2024. The largest group is 65 to 74, with 139 patients. 75% of them have cancer, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lee's median patient age at 73, with 27% women.

In 2024, Dr. Lee wrote 74 Medicare Part D claims for 36 patients. 95% of them were for generic drugs. CMS names the drug for 47 of them, across 1 drug with 11 or more claims each, at $269 in total drug cost. In 2023, CMS named 21 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Lee for performance year 2024, reported as part of a group. Dr. Lee accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lee as offering telehealth.

Dmand AI links 128 papers to Dr. Lee, published from 2011 to 2025. 2020 was the busiest year, with 18. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Radiosurgery. Dr. Lee has published most often in Int J Radiat Oncol Biol Phys. Dr. Lee's most frequent co-authors are Steven Hsesheng Lin, MD, PhD, Zhongxing Liao, MD and Joe Y. Chang, MD, PhD.

Dmand AI links Dr. Lee to 7 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung and Liver Neoplasms. Jonsson Comprehensive Cancer Center sponsors the most, 4.

CMS Open Payments shows 181 general payments to Dr. Lee from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 62% of the total. AstraZeneca Pharmaceuticals LP paid the most, $72,175. It also lists 10 research payments totaling $17,365 from 2020 to 2025.

Dr. Lee graduated from Harvard Medical School in 2003.

Dr. Lee is in network with 13 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.